GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ibex Technologies Inc (TSXV:IBT) » Definitions » ROE % Adjusted to Book Value

Ibex Technologies (TSXV:IBT) ROE % Adjusted to Book Value : 0.73% (As of Jan. 2024)


View and export this data going back to 1986. Start your Free Trial

What is Ibex Technologies ROE % Adjusted to Book Value?

Ibex Technologies's ROE % for the quarter that ended in Jan. 2024 was 1.40%. Ibex Technologies's PB Ratio for the quarter that ended in Jan. 2024 was 1.93. Ibex Technologies's ROE % Adjusted to Book Value for the quarter that ended in Jan. 2024 was 0.73%.


Ibex Technologies ROE % Adjusted to Book Value Historical Data

The historical data trend for Ibex Technologies's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ibex Technologies ROE % Adjusted to Book Value Chart

Ibex Technologies Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -46.47 15.01 10.80 19.36 15.44

Ibex Technologies Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.82 16.85 32.93 13.49 0.73

Competitive Comparison of Ibex Technologies's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Ibex Technologies's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ibex Technologies's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ibex Technologies's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Ibex Technologies's ROE % Adjusted to Book Value falls into.



Ibex Technologies ROE % Adjusted to Book Value Calculation

Ibex Technologies's ROE % Adjusted to Book Value for the fiscal year that ended in Jul. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=33.35% / 2.16
=15.44%

Ibex Technologies's ROE % Adjusted to Book Value for the quarter that ended in Jan. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=1.40% / 1.93
=0.73%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ibex Technologies ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Ibex Technologies's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Ibex Technologies (TSXV:IBT) Business Description

Traded in Other Exchanges
Address
5485 Pare Street, Suite 100, Montreal, QC, CAN, H4P 1P7
Ibex Technologies Inc is a company engaged in the production and sale of diagnostic products. It manufactures and markets enzymes for biomedical use, through its subsidiaries. It also manufactures and markets a series of arthritis assays that have applications in osteoarthritis research. It sells two product lines namely, Enzymes for in-vitro diagnostics and research, and Tests for osteoarthritis research. The group provides services like Filing and lyophilization of disposable diagnostic components, and Custom fermentation and purification of enzymes for diagnostic companies. Geographically, the firm sells its products in Canada, Germany, the U.S., the U.K., and other countries of which the majority of the revenue is generated from the U.S.

Ibex Technologies (TSXV:IBT) Headlines

No Headlines